Video

Dr. Deepak Kapoor on the Utilization of Prostate Biopsies

Deepak A. Kapoor, MD, president of the Large Urology Group Practice Association, discusses the implications of a large study looking at the detection of prostate cancer using prostate biopsies.

Deepak A. Kapoor, MD, president of the Large Urology Group Practice Association, chairman and CEO of Integrated Medical Professionals, PLLC, discusses the implications of a large study looking at the detection of prostate cancer using prostate biopsies.

The study examined the overall positive biopsy rates in 437,937 biopsies between 2005 and 2011. Samples were examined in both national reference and urology practice laboratories. Overall, the study found that positive rates were similar in both groups, at 40.3%. In addition to positive rates, the trial examined the number of vials collected per biopsy, which reached approximately 10 by 2011.

Kapoor notes that from a practicing urologists standpoint this data confirms that optimal detection of prostate cancer requires the collection of 10 to 12 cores. Additionally, from a health policy standpoint, these results indicate that positive biopsy rates are the same at both a national and individual practice level. Furthermore, for patients, these results can provide comfort that a biopsy is being performed for an appropriate clinical purpose and not financial gain.

<<<

View coverage from the 2013 GU Cancers Symposium

Related Videos
Paolo Caimi, MD
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD
Tiago Biachi, MD, PhD
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Louis Crain Garrot, MD
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec